PASI 100 response rates in moderate to severe psoriasis: a systematic literature review and analysis of clinical practice guidelines
- 21 February 2021
- journal article
- review article
- Published by Taylor & Francis Ltd in Journal of Dermatological Treatment
- Vol. 33 (3), 1661-1669
- https://doi.org/10.1080/09546634.2021.1890683
Abstract
Response to treatments in psoriasis can be assessed using the PASI response 50, 75, 90 or 100. Achieving a PASI 100 response would mean a complete resolution of the patient's basal lesions. Therefore, PASI 100 score has been increasingly used in the context of research, but its role in daily practice is currently controversial. (1) To analyze PASI 100 response rates to pharmacological treatments; (2) To examine clinical practice guidelines (CPGs) recommendations/comments on PASI 100. We conducted a systematic literature review (SLR). Selection criteria concerned patients with psoriasis, reporting PASI 100. Overall, 65 studies were included. Patients on methotrexate achieved at 16 weeks a PASI 100 of 7.3%. For TNF inhibitors rates were: 3.7–11.1% at 12 weeks, 13.7–20% at 16 weeks, 10.7–24% at 24 weeks and 21.8–34.8% at 1 year. IL-17 inhibitors achieved 23.3–44% at 12 weeks, 44.3–57.2% at 16 weeks, 39.7–67.5% at 24 weeks and 41.4–67.5% at 1 year. And the reported by IL-12/23 inhibitors were 12%/23.8% at 12 weeks, 32.7%/50% at 16 weeks, 44% at 24 weeks and 41.8%/56.3% at 1 year. PASI 100 response is scarcely commented in the CPGs. PASI 100 response rate is an endpoint fundamentally restricted to research.Keywords
Funding Information
- Spanish Academy of Dermatology and Venereology
- LEO Pharma
This publication has 97 references indexed in Scilit:
- Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 yearsBritish Journal of Dermatology, 2012
- Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: A phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL)Journal of Dermatological Science, 2011
- Relationship between methotrexate dosing and clinical response in patients with moderate to severe psoriasis: subanalysis of the CHAMPION studyBritish Journal of Dermatology, 2011
- How Good Are Clinical Severity and Outcome Measures for Psoriasis?: Quantitative Evaluation in a Systematic ReviewJournal of Investigative Dermatology, 2010
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)The Lancet, 2008
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)The Lancet, 2008
- Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trialJournal of the American Academy of Dermatology, 2008
- Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension studyJournal of the American Academy of Dermatology, 2006
- Psoriasis: epidemiology, clinical features, and quality of lifeAnnals Of The Rheumatic Diseases, 2005
- Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global AssessmentJournal of the American Academy of Dermatology, 2004